Skip to main content
RGBPP logo

Regen BioPharma, Inc. (RGBPP) Stock Price & Analysis

Regen BioPharma, Inc. (RGBPP) — price $0.00054 (-22.86%), as of the Nov 19, 2026 trading session.

Educational signal · not a buy or sell recommendation · How to read this

$0.00054 −$0.00016 (-22.86%)

Regen BioPharma, Inc. · RGBPP

Regen BioPharma, Inc. is a biotechnology company focused on developing regenerative medical applications. The company is in the early stages of identifying small molecules for immune cell activation in oncology and immune cell suppression for autoimmune diseases.

Price as of Nov 19, 2026

Key Statistics

Not scored: MoonshotScore covers actively traded US operating companies, not funds, preferred shares, warrants or thinly traded stocks.

Thousands of the 20,000+ US stocks here carry a MoonshotScore.

Scored companies in the same industry:

  • RLYB · Rallybio Corporation · 82 /100
  • ICCC · ImmuCell Corporation · 82 /100
  • ORMP · Oramed Pharmaceuticals Inc. · 72 /100

See all scored stocks →

Price & valuation

As of
MeasureValue
Latest provided price$0.00054
Change on the day-22.86%
52-week range$0.00054 – $0.06745
Shares traded on the day1.88M

Price & events

Other perspectives

Council score for Regen BioPharma (RGBPP): perspectives

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Legends Council

5 lenses, 0 current

AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built

Dalio-style lens (simulated) Ray Dalio Favorable read
Simons-style lens (simulated) Jim Simons Unfavorable read
Englander-style lens (simulated) Izzy Englander Neutral read
Klarman-style lens (simulated) Seth Klarman Unfavorable read
Moon AI lens (model) Neutral read

Read on: Sep 11, 2026 · older than the 27 hours refresh window; not a current reading

Munger's Mindset

Balance Sheet & Valuation · historical

Financial Health Weak
Margin of Safety Fairly Valued
Profit Margin Weak
Revenue Growth Weak
Debt/Equity Strong
ROE Neutral
Gross Margin Strong

Read on: Sep 11, 2026 · older than the 27 hours refresh window; not a current reading

How to read these bars and different assessments

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.

On Sep 11, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.

Readings on this page are from Nov 20, 2026, except a card that shows its own read date.

1 · What is it?

What is Regen BioPharma (RGBPP), and what does it report?

Short answer · as of

A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. Regen BioPharma, Inc. (RGBPP) is the company analyzed here. It employs 1 people and is led by David Raymond Koos. In Q3 FY2026 it reported revenue of $59,065 and net income of -$637,785.

2 · Latest results

What do the latest results show for Regen BioPharma (RGBPP)?

Short answer · as of

The most recent reported quarter, Q3 FY2026, carried revenue of $59,065.

Quarterly income statement — 4 quarters
Revenue, net income and earnings per share by quarter
PeriodRevenueNet incomeEPS
Q3 FY2026$59,065-$637,785-$0.0010 (diluted)
Q2 FY2026$59,065$991,927$0.01 (diluted)
Q1 FY2026$59,065-$967,853-$0.01 (diluted)
Q4 FY2025$59,366-$572,469-$0.01 (diluted)
3 · Financial strengths and risks

What are the financial strengths and risks for Regen BioPharma (RGBPP)?

Short answer · as of

The distress and quality screens read Piotroski F 2. Trailing ratios: ROE 19.7% · current ratio 0.05.

The records behind this page

Who holds the shares?

Institutional ownership reported through 13F filings.

Tracked investors

Which of the 16 named investors we follow held RGBPP in their latest 13F filing, and what they did against the filing before it.

None of the 16 tracked investors reported RGBPP in their latest 13F filing.

See all tracked investor portfolios

How to read these figures

These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.

What Investors Ask About Regen BioPharma (RGBPP)

These answers are editorial: 1 of these 1 answer is drawn from the RGBPP research dossier (written Mar 18, 2026 by gemini-2.0-flash). Figures in this section are not part of the source register.

What are the main risks for RGBPP?

Regen BioPharma, Inc. faces several significant risks typical of early-stage biotechnology companies. These include the risk of failure to secure funding for research and development, potential clinical trial failures and regulatory setbacks, competition from larger and more established biotech companies, intellectual property disputes, and the high volatility and liquidity risks associated with OTC trading.

Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 18, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.

Sources: the source register lists the 12 figures on this page — 7 from Financial Modeling Prep (FMP) and 5 with no recorded source. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.

Publication details and research sources
Published
Research standards
Methodology · Editorial policy · Corrections
Data Sources & Methodology
Figures come from Financial Modeling Prep (FMP). If FMP has no figure for a ticker, a price or fundamental may come from a Yahoo Finance fallback, or a price from an Alpaca fallback. SEC EDGAR is used only for filing links and company identity details (legal name, address), never for figures. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.